The driving force behind Allotex was the observation that the potential interest in synthetic corneal inlay technology was being dampened by the persistent biocompatibility issue. Recognizing the many technological changes that have occurred since Barraquer’s early pioneering epikeratophakia work, the company was established to develop human allograft inlays and onlays to satisfy a growing market need. The company was founded in 2014 by David Muller and he was joined in 2015 by Michael Mrochen. They have since established R & D facilities in Zurich, Switzerland and commercial facilities in Boston, Ma.
David Muller, PhD
Dr. Muller recognized the potential of using advanced methods to gently reshape the cornea and in 2007 founded Avedro, Inc., where he serves as the CEO.